Suppr超能文献

诊断时蛋白尿与淋巴瘤犬生存时间的关系。

Association of proteinuria at time of diagnosis with survival times in dogs with lymphoma.

机构信息

Friendship Hospital for Animals, Washington, DC, USA.

Department of Small Animal Clinical Sciences, University of Florida College of Veterinary Medicine, Gainesville, Florida, USA.

出版信息

J Vet Intern Med. 2024 Sep-Oct;38(5):2633-2641. doi: 10.1111/jvim.17144. Epub 2024 Jul 13.

Abstract

BACKGROUND

Lymphoma has been implicated as a possible cause of proteinuria in dogs. However, information about the potential importance of proteinuria in dogs with lymphoma is limited.

HYPOTHESIS

To determine if the presence of proteinuria at diagnosis was associated with median survival times in dogs with lymphoma and if lymphoma stage (I-V) or type (B vs T) were associated with the presence of proteinuria.

ANIMALS

Eighty-six client-owned dogs with a new diagnosis of lymphoma between 2008 and 2020.

METHODS

This was a retrospective cross-sectional study with dogs divided into proteinuric or nonproteinuric groups based on dipstick urine protein (protein ≥30 mg/dL classified as proteinuric) or a ratio of dipstick protein to urine specific gravity (ratio ≥1.5 classified as proteinuric). Dogs were excluded for: (1) treatment within 2 months with glucocorticoid, anti-neoplastic, or anti-proteinuric therapies, (2) diagnosed hypercortisolism or renal lymphoma, (3) active urine sediment, or (4) urine pH >8. Survival analysis utilized a Kaplan-Meier estimator and log-rank testing.

RESULTS

There was a significant difference in median survival between proteinuric and nonproteinuric dogs classified by urine dipstick (245 days [91, 399] vs 335 days [214, 456]; P = .03) or UP : USG (237 days [158, 306] vs 304 days [173, 434]; P = .03). No difference in prevalence of proteinuria was identified between stages (I-V) or types (B and T).

CONCLUSIONS AND CLINICAL IMPORTANCE

Proteinuria appears to be negatively associated with survival time in dogs newly diagnosed with lymphoma.

摘要

背景

淋巴瘤已被认为是犬蛋白尿的一个可能原因。然而,关于淋巴瘤犬蛋白尿潜在重要性的信息有限。

假设

确定诊断时蛋白尿的存在是否与淋巴瘤犬的中位生存时间相关,以及淋巴瘤分期(I-V)或类型(B 与 T)是否与蛋白尿的存在相关。

动物

2008 年至 2020 年间新诊断出淋巴瘤的 86 只患犬。

方法

这是一项回顾性病例对照研究,根据尿试纸尿蛋白(蛋白≥30mg/dL 定义为蛋白尿)或尿试纸蛋白与尿比重的比值(比值≥1.5 定义为蛋白尿)将犬分为蛋白尿组或非蛋白尿组。排除以下情况的犬:(1)2 个月内接受糖皮质激素、抗肿瘤或抗蛋白尿治疗;(2)诊断为皮质醇增多症或肾淋巴瘤;(3)有活跃的尿沉渣;或(4)尿液 pH 值>8。生存分析采用 Kaplan-Meier 估计器和对数秩检验。

结果

根据尿试纸(蛋白尿犬的中位生存时间为 245 天[91,399],而非蛋白尿犬为 335 天[214,456];P=0.03)或 UP:USG(蛋白尿犬的中位生存时间为 237 天[158,306],而非蛋白尿犬为 304 天[173,434];P=0.03)分类,蛋白尿犬与非蛋白尿犬的中位生存时间存在显著差异。在分期(I-V)或类型(B 和 T)之间,蛋白尿的发生率没有差异。

结论和临床意义

蛋白尿似乎与新诊断为淋巴瘤的犬的生存时间呈负相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b40/11423466/178c1c8730eb/JVIM-38-2633-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验